Login Register Cart 0
Generic placeholder image

CNS & Neurological Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5273
ISSN (Online): 1996-3181

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Editorial

Arachidonic Acid Mediators and their Role in Neurological Disease

Author(s): Malvina Hoxha

Volume 21, Issue 2, 2022

Published on: 31 December, 2021

Page: [106 - 107] Pages: 2

DOI: 10.2174/1871527321666220103204515

« Previous Next »
[1]
Marnett LJ, Rowlinson SW, Goodwin DC, Kalgutkar AS, Lanzo CA. Arachidonic acid oxigenation by COX-1 and COX-2. J Biol Chem 1999; 274: 22903-6.
[2]
Hoxha M, Rovati GE, & Cavanillas AB. The leukotriene receptor antagonist montelukast and its possible role in the cardiovascular field. Eur J Clin Pharmacol 2017; 73(7): 799-809.
[3]
Camara-Lemarroy CR, Gonzalez-Moreno EI, Guzman-de la Garza FJ, & Fernandez-Garza NE. Arachidonic acid derivatives and their role in peripheral nerve degeneration and regeneration. Sci World J 2012..
[4]
Muja N, Nelson JK, DeVries GH. Schwann cells express IP prostanoid receptors coupled to an elevation in intracellular cyclic AMP. J Neurosci Res 2007; 85(6): 1159-69.
[5]
Constable AL, Armati PJ, Hartung HP. DMSO induction of the leukotriene LTC4 by Lewis rat Schwann cells. J Neurol Sci 1999; 162(2): 120-6.

Rights & Permissions Print Cite
Article Metrics
20
2
© 2024 Bentham Science Publishers | Privacy Policy